Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Double-blind, Three-arm, 16 Week, Adaptive Phase III Clinical Study to Investigate the Efficacy and Safety of LAS41008 vs LASW1835 and vs Placebo in Patients With Moderate to Severe Chronic Plaque Psoriasis
Brief Summary: The aim of the study is to evaluate the efficacy and safety of LAS41008 in comparison to active control and placebo in patients with moderate to severe chronic plaque psoriasis


Options:
A: Arm Label: Investigational drug - Dose 1; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Investigational drug - Dose 2; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ACT-128800; Assigned to Arm(s): Investigational drug - Dose 1, Investigational drug - Dose 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching placebo
B: Arm Label: Secukinumab 150 mg load (Group 1); Type: EXPERIMENTAL; Interventions: Biological: Secukinumab | Arm Label: Secukinumab 150 mg no load (Group 2); Type: EXPERIMENTAL; Interventions: Biological: Secukinumab | Arm Label: Secukinumab 300 mg load (Group 3); Type: EXPERIMENTAL; Interventions: Biological: Secukinumab | Arm Label: Placebo arm 1 (Group 4); Type: PLACEBO_COMPARATOR; Interventions: Biological: Secukinumab | Arm Label: Placebo arm 2 (Group 4); Type: PLACEBO_COMPARATOR; Interventions: Biological: Secukinumab | Intervention Type: BIOLOGICAL; Name: Secukinumab; Assigned to Arm(s): Placebo arm 1 (Group 4), Placebo arm 2 (Group 4), Secukinumab 150 mg load (Group 1), Secukinumab 150 mg no load (Group 2), Secukinumab 300 mg load (Group 3)
C: Arm Label: Part 1: Tildrakizumab 5 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 1: Tildrakizumab 25 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 1: Tildrakizumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 1: Tildrakizumab 200 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part 2: Tildrakizumab 5 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 2: Tildrakizumab 25 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 2: Tildrakizumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 2: Tildrakizumab 200 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 3: Tildrakizumab 5 mg Follow-up; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Part 3: Tildrakizumab 25 mg Follow-up; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Part 3: Tildrakizumab 100 mg Follow-up; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Part 3: Tildrakizumab 200 mg Follow-up; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Part 3: Placebo Follow-up; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: tildrakizumab; Assigned to Arm(s): Part 1: Tildrakizumab 100 mg, Part 1: Tildrakizumab 200 mg, Part 1: Tildrakizumab 25 mg, Part 1: Tildrakizumab 5 mg, Part 2: Tildrakizumab 100 mg, Part 2: Tildrakizumab 200 mg, Part 2: Tildrakizumab 25 mg, Part 2: Tildrakizumab 5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part 1: Placebo
D: Arm Label: LAS41008; Type: EXPERIMENTAL; Interventions: Drug: LAS41008 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LASW1835; Type: ACTIVE_COMPARATOR; Interventions: Drug: LASW1835 | Intervention Type: DRUG; Name: LAS41008; Assigned to Arm(s): LAS41008 | Intervention Type: DRUG; Name: LASW1835; Assigned to Arm(s): LASW1835 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D